Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cryosection Histopathology Assessment and Review Machine (CHARM)
Glioblastoma Awareness Day: Combination provides ‘notable’ survival benefit
7/19/2023
tunnel - please keep posting .....
(I'm slow - but sooner or later I get there)
regards
OH - don't worry about the shitheads ......
Type 1 Diabetes - Novel Dendritic Cell Vaccine
FYI -
Avotres Presents Clinical Data for AVT001, a Novel Dendritic Cell Vaccine for Treatment of Type 1 Diabetes at ADA2023
7/19/2023
pgsd
thanks for posting this list
Project Orbis Partners
The U.S Food and Drug Administration together with the Australian Therapeutic Goods Administration (TGA) and Health Canada (HC) took part in the first Project Orbis collaborative review. Since then, other countries have joined and become Project Orbis Partners (POP).
'It could actually make me die': Doctor's ultimate sacrifice amid cancer battle
7/17/2023
(Not about DCVax) (Professor Richard Scolyer is a melanoma pathologist - who has GBM)
(His doc buddy is Georgina Long)(They wrote this paper - (melanoma)
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC))
His story -
There are very few people you meet who actually make a difference. Professor Richard Scolyer is one of them.
As the world's leading melanoma pathologist, he's saved thousands from a certain death sentence.
Now in a cruel twist he's been diagnosed with incurable brain cancer.
In a world first, Richard is using everything he knows about skin cancer to save his own life or buy himself more time.
"It could actually make me die more quickly and even have a more miserable death," Richard said.
"It's scary what the future holds … to be now faced with certain death in a relatively short period of time."
Just two months ago Richard was feeling terrific, travelling Europe and lecturing at medical conferences.
"We went on the hike, went above the snow line - incredible scenery in the mountains in Poland. But the next day when I woke up, I had a headache, a little bit confused and then ultimately I had a seizure," Richard said.
"Honestly, I felt normal. I didn't have any symptoms at all ... even in retrospect."
After flying back to Australia and undergoing multiple biopsies and scans, the worst possible prognosis was confirmed.
"The brain cancer is called glioblastoma … the sort of subtype of brain cancer I've got is the worst one," Richard said.
"Ultimately, everyone dies from it, no one gets cured. Pretty much … six to nine months is probably the average survival."
Now, Richard is using a special type of combination immunotherapy he helped pioneer with his colleague and best friend Professor Georgina Long, on his brain.
Georgina said "the new treatment plan is about giving drug therapy, immunotherapy".
"He's having combination immunotherapy before the definitive surgery and that's never been done," Georgina said.
"So it's not just cowboy stuff. It is very thoughtful, scientific; it's got to be based in science."
If it doesn't work for Richard, the research gained will be invaluable for future brain cancer patients.
For Richard, who has spent his life dedicated to medical research, he admits this could be his last big contribution.
"I want to give it a crack and see if they ... make a difference for me and ultimately, other brain cancer patients," he said.
I would love it if some of our knowledge and discoveries in melanoma - it's a small chance that it might actually work - but wow!"
Having spent time with Professor Richard Scolyer and his team, you can't help but feel inspired.
Richard is crossing his fingers and his toes and hoping for a miracle.
"I don't want to die ... I'm not ready to die yet. I'm too young to die. I love my life. I really do," he said
https://9now.nine.com.au/a-current-affair/aussie-doctor-professor-richard-scolyer-makes-sacrifice-after-brain-cancer-diagnosis/0e5f58e8-24bd-4dfe-b95f-186cc783a33c
Can't tell which therapy he is going with
The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRAF/MEK targeted therapy. In total, 192 patients were included; 141 received immunotherapy (104, combination of ipilimumab and nivolumab; 37, anti-PD-1 monotherapy), and 51 received targeted therapy.
https://pubmed.ncbi.nlm.nih.gov/33558722/
CHM meeting -------------------- Submission deadline
--------------------------------------------------------
28 and 29 September 2023 -----> 03 July 2023
26 and 27 October 2023 ---------> 31 July 2023
23 and 24 November 2023 -----> 28 August 2023
21 and 22 December 2023 -----> 25 September 2023
--------------------------------------------------------
25 and 26 January 2024 ------> 30 October 2023
22 and 23 February 2024 -----> 27 November 2023
21 and 22 March 2024 --------> 25 December 2023
--------------------------------------------------------
25 and 26 April 2024 --------> 29 January 2024
30 and 31 May 2024 --------> 04 March 2024
--------------------------------------------------------
https://www.gov.uk/guidance/marketing-authorisation-application-submission-dates-for-150-days-national-and-european-commission-decision-reliance-procedures
thanks
but pgsd found a bigger problem which I completely missed -
Doctors use precision medicine to show melanoma drugs can shrink rare brain tumor by 90%
July 13, 2023
vorasidenib
https://clinicaltrials.gov/search?intr=vorasidenib%20
https://clinicaltrials.gov/study/NCT05592743?intr=vorasidenib%20&rank=2
The French take 30 days off in August for vacation - at least they use to - not sure which month the English
take off and is it for the same 30 days the French do.
Vaccine (mice) delivers a boost to T cell therapy
7/5/2023
Horse - I don't know